4-Methyl-3-oxo-4-aza-5α-androst-1-ene-17β-N-aryl-carboxamides: an approach to combined androgen blockade [5α-reductase inhibition with androgen receptor binding in vitro]
- 31 March 1997
- journal article
- research article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 60 (5-6) , 303-309
- https://doi.org/10.1016/s0960-0760(96)00199-9
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Effect of MK-386, a novel inhibitor of type 1 5 alpha-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in menJournal of Clinical Endocrinology & Metabolism, 1996
- Effects of GI198745 (GG745), A Novel 5-alpha Reductase (5AR) Inhibitor, on Dihydro-Testosterone (DHT)Clinical Pharmacology & Therapeutics, 1996
- Commentary on maximal androgen blockade in prostate cancer: A theory to put into practice?The Prostate, 1995
- Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patientsThe Lancet, 1995
- Synthesis and in Vitro Evaluation of 4-Substituted N-(1,1-Dimethylethyl)-3-oxo-4-androstene-17.beta.-carboxamides as 5.alpha.-Reductase Inhibitors and AntiandrogensJournal of Medicinal Chemistry, 1995
- Chemoprevention for prostate cancerCancer, 1995
- Synthesis and in Vitro Activity of 17.beta.-(N-Alkyl/arylformamido and N-alkyl/arylalkyl/arylamido)-4-methyl-4-aza-3-oxo-5.alpha.-androstan-3-ones as Inhibitors of Human 5.alpha.-Reductases and Antagonists of the Androgen ReceptorJournal of Medicinal Chemistry, 1995
- Finasteride: a clinical reviewBiomedicine & Pharmacotherapy, 1995
- STEROID 5α-REDUCTASE: TWO GENES/TWO ENZYMESAnnual Review of Biochemistry, 1994
- New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgensThe Prostate, 1983